Women are routinely warned that lowering cholesterol with a statin will stop a heart attack and extend their lives. Their doctor sounds really convincing.
But what happens when we stop promoting relative-risk headlines and examine the number of women who must take the drug for one woman to benefit? The sales pitch becomes much less impressive.
Women Were Underrepresented in the Statin Trials
Women develop cardiovascular disease differently from men. Hormones, menopause, pregnancy history, autoimmune disease, metabolic health and inflammatory patterns can all influence risk.
Yet women have historically been underrepresented in the clinical trials used to justify statin prescriptions. One of the largest statin meta-analyses included more than 174,000 participants, but women represented only about one-quarter of them. In another analysis of statins for secondary prevention, women accounted for only about one-fifth of participants.
Researchers then apply the overall findings to millions of women as if female-specific evidence were equally robust. It isn’t.
This does not mean statins can never reduce an event in a woman. It means the certainty and magnitude of that benefit deserve far more scrutiny than the pharmaceutical message allows.
Look at the NNT, Not the Headline
The number needed to treat, or NNT, tells us how many people must take a treatment for a specified period to prevent one particular outcome. This concept is very important.
The JUPITER trial is frequently used to defend statin therapy in women without known cardiovascular disease. It studied rosuvastatin in women aged 60 and older who had elevated hs-CRP, a marker of inflammation, but no previous cardiovascular event.
The estimated five-year NNT for women was 31 to prevent one composite outcome consisting of heart attack, stroke, revascularization or death. That means 31 women would need to take rosuvastatin for five years for one woman to avoid one of those combined outcomes. The other 30 women would not receive that measured benefit.
And notice the word “composite.” A revascularization procedure is counted alongside a heart attack, stroke or death. Composite outcomes can make a treatment look more impressive by combining multiple events of dramatically different importance.
When investigators restricted the analysis to the harder outcomes of heart attack, stroke or death, the estimated five-year NNT for women increased to approximately 52. Fifty-one of those women would receive no such measured benefit.
There is another important limitation: JUPITER was stopped after a median follow-up of only 1.9 years. The five-year NNT was an extrapolation, not an observed five-year trial result.
These are not zero benefits. But they are not massive benefits either, and they certainly do not justify placing every woman with an elevated cholesterol result on a lifelong pharmaceutical.
What About Women Who Already Have Cardiovascular Disease?
The evidence is stronger when a woman has already experienced a heart attack or has established cardiovascular disease. Statins can reduce recurrent coronary events and the need for additional cardiac procedures.
But even in secondary-prevention analyses, women-specific reductions in total mortality and stroke have not consistently reached statistical significance. That is an important distinction.
Reducing a composite endpoint is not automatically the same as preventing death. Lowering LDL-C is not automatically the same as extending life. Changing a laboratory number is not automatically the same as creating health. If you want the fuller picture on cholesterol testing, my write-up on ApoB, the cholesterol test your doctor probably is not ordering, is a good next read.
Women deserve to know exactly which outcome was reduced, how many women had to take the drug, how long they were treated and whether the outcome was a heart attack, a procedure or a death.
The Other Women Still Face the Side Effects
The NNT describes how many women must be treated for one to benefit. It does not mean the remaining women are unaffected. They still take the drug. They still alter an essential biological pathway. And some experience adverse effects.
Women taking statins have reported muscle pain, weakness, fatigue and exercise intolerance. Women also appear more likely to discontinue treatment because of muscle symptoms.
Statins can raise glucose and increase the risk of newly diagnosed diabetes. In the female JUPITER subgroup, rosuvastatin produced a statistically significant increase in new-onset diabetes. This is especially concerning for postmenopausal women already struggling with insulin resistance, elevated glucose or metabolic dysfunction.
Liver-enzyme abnormalities can occur. Drug interactions matter. Pregnancy and breastfeeding create additional concerns.
So the honest calculation is not simply, “Can a statin reduce an event?” The real question is:
- How many women must take the drug?
- How many actually benefit?
- Which outcome is prevented — a heart attack, a procedure, or a death?
- And what happens to everyone else?
These same questions apply to every cholesterol drug on the market, including the newer injectables. I walked through that reasoning in my thoughts on Repatha and again with the newly approved cholesterol drug Lipfendra.
The Goal Is Not a Tiny Reduction in Risk
I am not interested in spending decades chasing cholesterol while ignoring why a woman is inflamed, insulin resistant, oxidatively stressed or developing vascular dysfunction.
The goal is not a marginal improvement in a pharmaceutical trial. The goal is a massive reduction in cardiac risk. The goal is to help women avoid heart attacks, strokes, procedures, disability and premature death while protecting their energy, brain, muscles and metabolic health.
That requires looking beyond cholesterol. Cardiovascular disease develops from too much bad stuff and not enough good stuff. Toxins, ultra-processed food, poor sleep, artificial light, chronic stress, mold exposure, nutrient deficiencies, insulin resistance and oxidative stress can damage the endothelium and create the conditions in which cardiovascular disease develops.
A statin does not identify or correct those causes.
The 100 Year Heart Method
The 100 Year Heart Method is designed to identify and address the factors driving cardiovascular risk instead of managing one cholesterol number.
We focus on eating well, living well and thinking well. We evaluate inflammation, oxidative stress, metabolic health, nutrient status, toxins and the health of the vascular system. We test. We do not guess.
Then we build a personalized strategy using nutrition, lifestyle, targeted testing, evidence-based supplements and biohacking strategies. No single test, drug or supplement creates a 100 Year Heart. The goal is to address the entire environment in which cardiovascular disease develops. If you want help applying this to your own numbers, you can schedule a free heart health discovery call.
Looking for a Better Test Than Cholesterol?
Cholesterol is one piece of information. It does not tell you whether your body is under oxidative stress right now.
The Oxidative Stress Test package evaluates oxidative damage that can injure cell membranes, lipoproteins and blood vessels. It also includes the Heart Attack Risk questionnaire and a review with a Natural Heart Doctor practitioner to help connect your results with your next steps.
If you want to understand what may be driving your cardiovascular risk, rather than simply measuring cholesterol, the Oxidative Stress Test package is the place to start.
Looking for Nutritional Support?
OptiLipid is our comprehensive botanical formula designed to support healthy lipid metabolism, inflammatory balance and the body’s natural cholesterol-clearance pathways. It includes berberine, resveratrol, green tea, silymarin, quercetin, curcumin and ginger.
OptiLipid is not a substitute for identifying root causes. It is one part of a comprehensive strategy designed to support the liver, metabolism and cardiovascular system.
Women deserve more than a prescription based on one cholesterol result. They deserve the complete story — the real probability of benefit, the potential harms, and the root causes that conventional cholesterol-centered care continues to overlook.
The goal is not better cholesterol. The goal is a stronger heart, healthier blood vessels and a life that remains vibrant for decades to come.
Frequently Asked Questions
NNT is the number needed to treat — how many women must take a drug for a set period for one woman to avoid one specific outcome. In the JUPITER trial the estimated five-year NNT for women was 31 for a composite outcome, and about 52 when the analysis was limited to heart attack, stroke or death.
No. One of the largest statin meta-analyses included more than 174,000 participants, but women made up only about one-quarter of them. In one secondary-prevention analysis women were only about one-fifth of participants, so female-specific evidence is far less robust than the marketing implies.
Women have reported muscle pain, weakness, fatigue and exercise intolerance, and appear more likely to stop treatment because of muscle symptoms. Statins can also raise glucose and increase the risk of newly diagnosed diabetes, which matters especially for postmenopausal women with insulin resistance.
The evidence is stronger for women with established cardiovascular disease, where statins can reduce recurrent coronary events and the need for further procedures. Even so, women-specific reductions in total mortality and stroke have not consistently reached statistical significance.
Inflammation, oxidative stress, metabolic health, nutrient status, toxin exposure and the health of the vascular system all shape cardiovascular risk. The Oxidative Stress Test package evaluates oxidative damage that can injure cell membranes, lipoproteins and blood vessels, and includes a practitioner review.
References
- Fulcher J, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. The Lancet. 2015.
- Mora S, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Circulation. 2010.
- Ridker PM, et al. Number needed to treat with rosuvastatin to reduce first cardiovascular events and death among men and women. Circulation: Cardiovascular Quality and Outcomes. 2009.
- Gutierrez J, et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Archives of Internal Medicine. 2012.
- Reith C, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of randomized, double-blind trials. The Lancet. 2022.
